<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="proliferative capacity. Although the mechanism of initiation and progression of" exact="cancer" post="has been well established, the successful treatment of cancer"/>
 <result pre="of cancer has been well established, the successful treatment of" exact="cancer" post="remains a huge challenge facing the lack of early"/>
 <result pre="the implementation of efficient prevention and treatment strategies to curb" exact="cancer" post="deaths. Investigating small molecule antitumor agents, which could decrease"/>
 <result pre="recently approved for the treatment of metastatic or otherwise advanced" exact="breast cancer" post="[18]. SNS-032 (2) is a potent, selective inhibitor of"/>
 <result pre="approved for the treatment of metastatic or otherwise advanced breast" exact="cancer" post="[18]. SNS-032 (2) is a potent, selective inhibitor of"/>
 <result pre="approved for the oral treatment of CML and Philadelphia chromosome-positive" exact="acute lymphoblastic leukemia" post="[23]. Fig. 1 Development of 2-aminothiazole core in anticancer"/>
 <result pre="for the oral treatment of CML and Philadelphia chromosome-positive acute" exact="lymphoblastic leukemia" post="[23]. Fig. 1 Development of 2-aminothiazole core in anticancer"/>
 <result pre="the oral treatment of CML and Philadelphia chromosome-positive acute lymphoblastic" exact="leukemia" post="[23]. Fig. 1 Development of 2-aminothiazole core in anticancer"/>
 <result pre="their antiproliferative activity on human prostate (PC-3) and ovarian (SKOV-3)" exact="cancer" post="cell lines. Based on preliminary results, compounds 7a, 7b,"/>
 <result pre="one and exhibited moderate activity on colon, melanoma, renal, and" exact="breast cancer" post="cell lines. Compounds 8d, 8e, 8f, and 8a exhibited"/>
 <result pre="and exhibited moderate activity on colon, melanoma, renal, and breast" exact="cancer" post="cell lines. Compounds 8d, 8e, 8f, and 8a exhibited"/>
 <result pre="agents. According to results, compound 9 showed high selectivity against" exact="leukemia" post="and prostate cancer exhibited subpanel MG-MID GI50 value of"/>
 <result pre="to results, compound 9 showed high selectivity against leukemia and" exact="prostate cancer" post="exhibited subpanel MG-MID GI50 value of 3.51 and 5.15â€‰ÂµM,"/>
 <result pre="results, compound 9 showed high selectivity against leukemia and prostate" exact="cancer" post="exhibited subpanel MG-MID GI50 value of 3.51 and 5.15â€‰ÂµM,"/>
 <result pre="compounds were screened for in vitro antiproliferative activity against four" exact="cancer" post="cell lines containing A549, HeLa, HT29, and Karpas299 human"/>
 <result pre="cancer cell lines containing A549, HeLa, HT29, and Karpas299 human" exact="cancer" post="cell lines. Some of these synthesized compounds displayed remarkable"/>
 <result pre="outstanding growth inhibitory effects against A549, HeLa, HT29, and Karpas299" exact="cancer" post="cell lines, especially for HT29 cells (IC50â€‰=â€‰2.01â€‰ÂµM). Based on"/>
 <result pre="U251 cells and human melanoma WM793 cells, comparing to the" exact="leukemia" post="cells. Meantime, these compounds created low toxicity to pseudo-normal"/>
 <result pre="purpose to find novel active scaffold against sensitive and resistant" exact="cancer" post="cells, Millet and coworkers reported the synthesis and evaluation"/>
 <result pre="both sensitive and resistant cell lines of melanoma, leukemia, and" exact="pancreatic cancer" post="cells. All tested compounds exhibited an activity in the"/>
 <result pre="sensitive and resistant cell lines of melanoma, leukemia, and pancreatic" exact="cancer" post="cells. All tested compounds exhibited an activity in the"/>
 <result pre="compound 12 exhibited high in vitro cellular activities against melanoma," exact="pancreatic cancer," post="and chronic myeloid leukemia and displayed a good selectivity"/>
 <result pre="high in vitro cellular activities against melanoma, pancreatic cancer, and" exact="chronic myeloid leukemia" post="and displayed a good selectivity against three cancer cells"/>
 <result pre="in vitro cellular activities against melanoma, pancreatic cancer, and chronic" exact="myeloid leukemia" post="and displayed a good selectivity against three cancer cells"/>
 <result pre="vitro cellular activities against melanoma, pancreatic cancer, and chronic myeloid" exact="leukemia" post="and displayed a good selectivity against three cancer cells"/>
 <result pre="chronic myeloid leukemia and displayed a good selectivity against three" exact="cancer" post="cells at its active concentration. Compound 12 also showed"/>
 <result pre="tumor cell lines. Compound 13 indicated significant activity toward RPMI-8226" exact="leukemia" post="cell line (GI50â€‰=â€‰0.08â€‰ÂµM), and showed a wide spectrum activity"/>
 <result pre="cell lines except the higher activity of compound 13 against" exact="colon cancer" post="cell lines and leukemia RPMI-8226 cell line. Based on"/>
 <result pre="lines except the higher activity of compound 13 against colon" exact="cancer" post="cell lines and leukemia RPMI-8226 cell line. Based on"/>
 <result pre="activity of compound 13 against colon cancer cell lines and" exact="leukemia" post="RPMI-8226 cell line. Based on the SAR studied, in"/>
 <result pre="derivatives with morpholino group or N-phenylpiperazino exhibited activity against MOLT-4" exact="leukemia" post="cell line. Compound with N-phenylpiperazino was more active than"/>
 <result pre="this derivative affect on another cell lines of SNB-19 CNS" exact="cancer" post="and IGORV1 ovarian cancer. In the 3-aminopropanamido series, compound"/>
 <result pre="on another cell lines of SNB-19 CNS cancer and IGORV1" exact="ovarian cancer." post="In the 3-aminopropanamido series, compound 13 with diethylamino was"/>
 <result pre="pyrrolidino and 14b with piperidino displayed significant activity against the" exact="leukemia" post="cell lines RPMI-8226 and SR. Among these three series,"/>
 <result pre="efficacy of TH-39 as an anti-cancer compound for treatment of" exact="chronic myeloid leukemia" post="(Fig. 5) [42]. Fig. 5 2-Aminothiazole scaffold containing amide"/>
 <result pre="of TH-39 as an anti-cancer compound for treatment of chronic" exact="myeloid leukemia" post="(Fig. 5) [42]. Fig. 5 2-Aminothiazole scaffold containing amide"/>
 <result pre="TH-39 as an anti-cancer compound for treatment of chronic myeloid" exact="leukemia" post="(Fig. 5) [42]. Fig. 5 2-Aminothiazole scaffold containing amide"/>
 <result pre="to many hundred micromolar). Overexpression of KPBN1 occurred in many" exact="cancer" post="cells whereas siRNA-induced inhibition of KPNB1 significantly inhibited proliferation"/>
 <result pre="cells whereas siRNA-induced inhibition of KPNB1 significantly inhibited proliferation of" exact="cancer" post="cells, while did not affect normal cells. A pyrrole"/>
 <result pre="compound 19 (a valine prodrug) indicated potential cytotoxicity against some" exact="cancer" post="cells such as P-gp overexpressing MDR positive cell line"/>
 <result pre="scaffold were synthesized and tested for antitumor activities against two" exact="cancer" post="cell line of human lung cancer (H1299) and human"/>
 <result pre="for antitumor activities against two cancer cell line of human" exact="lung cancer" post="(H1299) and human glioma (SHG-44). Some compounds exhibited moderate"/>
 <result pre="antitumor activities against two cancer cell line of human lung" exact="cancer" post="(H1299) and human glioma (SHG-44). Some compounds exhibited moderate"/>
 <result pre="cancer cell line of human lung cancer (H1299) and human" exact="glioma" post="(SHG-44). Some compounds exhibited moderate to good activities against"/>
 <result pre="(SHG-44). Some compounds exhibited moderate to good activities against two" exact="cancer" post="cell lines. Among these compounds, the promising analogue 20"/>
 <result pre="21 indicated potent and selective antiproliferative activity against human K563" exact="leukemia" post="cells (IC50â€‰=â€‰16.3â€‰ÂµM) compared with dasatinib (IC50â€‰=â€‰11.08â€‰ÂµM). Compound 21 was"/>
 <result pre="21 with acetylamide group indicated good selectivity against human K563" exact="leukemia" post="cells (Fig. 5) [48]. Misra et al. synthesized a"/>
 <result pre="an ip/ip P388 murine tumor model and an A2870 human" exact="ovarian cancer" post="xenograft tumor mouse model identified the compound 2. SNS-032"/>
 <result pre="ip/ip P388 murine tumor model and an A2870 human ovarian" exact="cancer" post="xenograft tumor mouse model identified the compound 2. SNS-032"/>
 <result pre="tested compounds indicated high cytotoxicity against a panel of human" exact="cancer" post="cell lines. Compounds 25a, 25b, and 26 significantly inhibited"/>
 <result pre="Compound 25a showed equal cytotoxicity compared to SAHA on five" exact="cancer" post="cell lines and illustrated equivalent efficacy compared to SAHA"/>
 <result pre="tested compounds, compound 27 indicated strong antiproliferative activity against two" exact="cancer" post="cell lines HeLa and A549. Compound 27 exhibited most"/>
 <result pre="abnormalities, and apoptosis induction. This compound exhibited good selectivity against" exact="cancer" post="cells while was not active toward normal cells. In"/>
 <result pre="of C-4â€² 4-methoxyphenoxy demonstrated potential antiproliferative activity against the four" exact="cancer" post="cell lines (IC50â€‰=â€‰32.0-48.6â€‰nM) and movement of the C-4 methoxy"/>
 <result pre="antiproliferative activity of these derivatives were assessed against four human" exact="cancer" post="cell lines HCT116, MCF-7, U87 MG, and A549 cell"/>
 <result pre="retained the antiproliferative activity (IC50â€‰=â€‰13â€‰nM against PI3KÎ±) against the four" exact="cancer" post="cell lines and inhibition of PI3K and mTOR. Replacement"/>
 <result pre="against a wide range of subpanel tumor cell lines especially" exact="leukemia" post="and melanoma subpanels was seen in due to derivatization"/>
 <result pre="The cytotoxic effects of these compounds determined on several human" exact="cancer" post="cell lines (A549, HepG2, HeLa, and LOVO cells) and"/>
 <result pre="was evaluated for their in vitro antitumor activity on human" exact="lung cancer" post="cell. Among these components, 47 indicated greater cytotoxic effects"/>
 <result pre="evaluated for their in vitro antitumor activity on human lung" exact="cancer" post="cell. Among these components, 47 indicated greater cytotoxic effects"/>
 <result pre="in gliomas, melanomas and NSCLCs and impairing its activity kills" exact="cancer" post="cells and an efficient approach to killing MDR cancer"/>
 <result pre="kills cancer cells and an efficient approach to killing MDR" exact="cancer" post="cells. A number of thiazole derivatives including 4-halo-2,5-disubtituted-1,3- thiazoles"/>
 <result pre="in vitro growth inhibitory activity against a panel of 6" exact="glioma" post="cell lines. Compounds 48a and 48b exhibited ~ 10"/>
 <result pre="independent of the inherent resistance to pro-apoptotic stimulus related with" exact="cancer" post="cell lines. Derivatives 48a and 48b demonstrated similar inhibition"/>
 <result pre="POH as noncardiotonic steroid-related compound demonstrated remarkable therapeutic benefits to" exact="glioma" post="patients. POH created its anti-glioma activity at least partly"/>
 <result pre="cell line. Compounds 50b showed moderate activity against ovarian OVCAR-4" exact="cancer" post="cell line (mean percentage cell growth = 77.23%). The"/>
 <result pre="to increase the potency towards CNS SNB-75 and Renal UO-31" exact="cancer" post="cell lines. Also, unsubstituted phenyl ring showed more enhanced"/>
 <result pre="al. Antiproliferative activity of these compounds were evaluated in three" exact="cancer" post="cell lines namely, Hs578T, HeLa, and HepG2. According to"/>
 <result pre="results of compounds 51a and 51b on the triple negative" exact="breast cancer" post="cell line Hs578T deserved special mention. C-6 substitution of"/>
 <result pre="of compounds 51a and 51b on the triple negative breast" exact="cancer" post="cell line Hs578T deserved special mention. C-6 substitution of"/>
 <result pre="(51a) or chloro group increases the compound entry into the" exact="cancer" post="cell. Replacing methyl (51a) with chlorine on C-6 position"/>
 <result pre="MCF7), estrogen-negative (HS-578T, MDA-MB-435, MDA-MB-231/ATCC, BT-549) and adriamycin-resistant (NCI/ADR-RES) human" exact="breast cancer" post="cell lines. The GI50 values of these compounds defined"/>
 <result pre="estrogen-negative (HS-578T, MDA-MB-435, MDA-MB-231/ATCC, BT-549) and adriamycin-resistant (NCI/ADR-RES) human breast" exact="cancer" post="cell lines. The GI50 values of these compounds defined"/>
 <result pre="sulfur linkage showed significantly more active on different types of" exact="breast cancer" post="cells. The most GI50 on human breast tumor cells"/>
 <result pre="linkage showed significantly more active on different types of breast" exact="cancer" post="cells. The most GI50 on human breast tumor cells"/>
 <result pre="number of aminothiazoles derivatives were prepared and assessed against eight" exact="cancer" post="cells and two non-cancer fibroblasts. Some of compounds exhibited"/>
 <result pre="derivatives. Antitumor activity of these derivatives was measured on six" exact="cancer" post="cell lines namely NUGC, HR, DLD1, HA22T, HEPG2, MCF,"/>
 <result pre="and DNA fragmentation, compound 58 showed apoptosis inducer effect in" exact="cancer" post="cell line tested (Fig. 10) [76]. Considering Combretastatin A-4"/>
 <result pre="growth at nanomolar concentrations, exhibiting inhibitory effects even on multidrug-resistant" exact="cancer" post="cell lines through its interaction with tubulin at the"/>
 <result pre="series, with IC50 values of 0.03-0.9â€‰nM against five of seven" exact="cancer" post="cell lines. The most active compounds retained full activity"/>
 <result pre="lines. The most active compounds retained full activity in multidrug-resistant" exact="cancer" post="cells and acted through the colchicine site of tubulin."/>
 <result pre="against breast carcinoma (MCF-7), human colon adenocarcinoma (SW480), and human" exact="liver cancer" post="(HepG2) cell lines using MTT assay. Also, the effect"/>
 <result pre="breast carcinoma (MCF-7), human colon adenocarcinoma (SW480), and human liver" exact="cancer" post="(HepG2) cell lines using MTT assay. Also, the effect"/>
 <result pre="improvement of defects. N-alkylation of 2-amino thiazole increased potency on" exact="breast cancer" post="cells. Compound 65 with N-allyl substituent was more potent"/>
 <result pre="of defects. N-alkylation of 2-amino thiazole increased potency on breast" exact="cancer" post="cells. Compound 65 with N-allyl substituent was more potent"/>
 <result pre="of derivatives showed potential antiproliferative activity on breast, pancreatic, and" exact="prostate cancer," post="whereas their aqueous solubility increased. Among these compounds, compound"/>
 <result pre="Also, in A549 cells its efficacy to inhibit EMT in" exact="cancer" post="cells was validated through MAP kinases (ERK and JNK)"/>
 <result pre="greater than âˆ’4, therefore they have a significant activity against" exact="cancer" post="cells. The mean graph midpoint (MG-MID) values for standard"/>
 <result pre="compound melphalan. Derivative 74b was the most active compound against" exact="colon cancer" post="(log10 GI50â€‰=â€‰âˆ’6.64), that was more than cis-diaminodichloroplatinum (Fig. 15)"/>
 <result pre="melphalan. Derivative 74b was the most active compound against colon" exact="cancer" post="(log10 GI50â€‰=â€‰âˆ’6.64), that was more than cis-diaminodichloroplatinum (Fig. 15)"/>
 <result pre="great selectivity for CDKs. This compound remarkably suppressed proliferation of" exact="cancer" post="cell lines which there was a correlation between the"/>
 <result pre="thiazolyl-chalcones (E)-1-(4-methyl-2-arylaminothiazol-5-yl)-3-arylprop-2-en-1-ones and assessed activity of these compounds against different" exact="cancer" post="cell lines BGC-823, PC-3, NCI-H460, BEL-7402 by MTT assay."/>
 <result pre="NCI-H460, BEL-7402 by MTT assay. Some compounds indicated activity on" exact="cancer" post="cells with IC50 value below 10â€‰ÂµM. According to the"/>
 <result pre="compounds for their antiproliferative activity was performed against three human" exact="cancer" post="cell lines namely, gastric adenocarcinoma (SGC-7901), lung adenocarcinoma (A549),"/>
 <result pre="cell lines namely, gastric adenocarcinoma (SGC-7901), lung adenocarcinoma (A549), and" exact="fibrosarcoma" post="(HT-1080). Most of compounds exhibited moderate activity in the"/>
 <result pre="with IC50 values between 0.36 and 0.86â€‰Î¼M in the three" exact="cancer" post="cell lines and disruption of tubulin microtubule dynamics in"/>
 <result pre="in vitro cytotoxicity investigation of the compounds on six human" exact="cancer" post="cell lines (MCF-7, HL-60, SK-MEL-2, A549, OVCAR-3, and SW620)"/>
 <result pre="of 2.32 and 8.16â€‰Âµg/mL respectively, whereas, 79b was active against" exact="lung cancer" post="cell line A549 with GI50 value of 1.61â€‰Âµg/mL. Moreover,"/>
 <result pre="2.32 and 8.16â€‰Âµg/mL respectively, whereas, 79b was active against lung" exact="cancer" post="cell line A549 with GI50 value of 1.61â€‰Âµg/mL. Moreover,"/>
 <result pre="tested compounds showed selective dose-response towards the breast, leukemia, and/or" exact="lung cancer" post="cell lines. In SAR studies, the phenyl ring (R4)"/>
 <result pre="compounds showed selective dose-response towards the breast, leukemia, and/or lung" exact="cancer" post="cell lines. In SAR studies, the phenyl ring (R4)"/>
 <result pre="Compound 83 showed apoptosis induction and cell death in 786-O" exact="renal cell carcinoma" post="cells with EC50â€‰=â€‰5â€‰ÂµM and suppressed activation of STAT3 more"/>
 <result pre="could be inhibited glucose uptake and enhanced ROS generation in" exact="cancer" post="cells. Derivatives 84a and 84b exhibited strong activity against"/>
 <result pre="simplified ROS generation and decreased NADPH/NADP levels and finally induced" exact="cancer" post="cell death through energy restriction, at least in part."/>
 <result pre="increase in survival time versus untreated control against P388 murine" exact="leukemia" post="in mice (Fig. 17) [100]. Tomita et al. discovered"/>
 <result pre="oral efficacy of 88 was further determined in an adjuvant" exact="arthritis" post="model in rats. The oral efficacy of these inhibitors"/>
 <result pre="of chain in derivatives showed significantly less inhibitory against A2780" exact="cancer" post="cells and a reasonable activity against ECRF24 cells. Moreover,"/>
 <result pre="assays, representative compound exhibited a significant antiproliferative activity on two" exact="cancer" post="cell lines (SHSY5Y and K562). The modeling studies were"/>
 <result pre="as dual Bcr-Abl/HDAC inhibitors displayed high antiproliferative activities against human" exact="leukemia" post="cell line (K562) and prostate cancer cell line (DU145)"/>
 <result pre="high antiproliferative activities against human leukemia cell line (K562) and" exact="prostate cancer" post="cell line (DU145) (Fig. 19) [107]. Fig. 19 Hybridization"/>
 <result pre="antiproliferative activities against human leukemia cell line (K562) and prostate" exact="cancer" post="cell line (DU145) (Fig. 19) [107]. Fig. 19 Hybridization"/>
 <result pre="Sulfo-Rhodamine-B stain (SRB) assay against four human tumor cell lines;" exact="breast cancer" post="MCF-7, liver cancer HepG2, lung carcinoma A549, and colorectal"/>
 <result pre="stain (SRB) assay against four human tumor cell lines; breast" exact="cancer" post="MCF-7, liver cancer HepG2, lung carcinoma A549, and colorectal"/>
 <result pre="assay against four human tumor cell lines; breast cancer MCF-7," exact="liver cancer" post="HepG2, lung carcinoma A549, and colorectal cancer HCT116. The"/>
 <result pre="against four human tumor cell lines; breast cancer MCF-7, liver" exact="cancer" post="HepG2, lung carcinoma A549, and colorectal cancer HCT116. The"/>
 <result pre="human tumor cell lines; breast cancer MCF-7, liver cancer HepG2," exact="lung carcinoma" post="A549, and colorectal cancer HCT116. The reference drug in"/>
 <result pre="breast cancer MCF-7, liver cancer HepG2, lung carcinoma A549, and" exact="colorectal cancer" post="HCT116. The reference drug in this study was doxorubicin."/>
 <result pre="cancer MCF-7, liver cancer HepG2, lung carcinoma A549, and colorectal" exact="cancer" post="HCT116. The reference drug in this study was doxorubicin."/>
 <result pre="by Jiao et al. was carried out against human cervix" exact="cancer" post="(HeLa) cell line. Based on the antitumor bioassay, most"/>
 <result pre="tumor cell lines including HL-60; leukemia, BGC-823; stomach and HEP-2;" exact="larynx cancer" post="by the MTT method and the SRB method. Among"/>
 <result pre="cell lines including HL-60; leukemia, BGC-823; stomach and HEP-2; larynx" exact="cancer" post="by the MTT method and the SRB method. Among"/>
 <result pre="further in vitro assay against a wide panel of human" exact="cancer" post="cell lines and the most active compounds were selected"/>
 <result pre="assessed for their in vitro cytotoxic activity against different human" exact="cancer" post="cell lines including MCF7, HCT116, and DU145 and one"/>
 <result pre="(Âµg/mL) and 20â€‰Â±â€‰2.1 (Âµg/mL), respectively. The major problem encountered in" exact="cancer" post="chemotherapy is mainly because of iron deficiency finally leads"/>
 <result pre="for their anticancer activity on fibroblast cells (BALB/3T3) and seven" exact="cancer" post="cell lines (AGS, HeLa, PaTu8988t, HT-29, U87-MG, A549, and"/>
 <result pre="edn., PA: Williams and Wilkins, Media; 2002. p. 822. 2.StewartBWWildCPWorld" exact="cancer" post="report 20142015Lyon, FranceInternational Agency for Research on Cancer (IARC)"/>
 <result pre="evaluation of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human" exact="breast cancer" post="cell proliferationBioorg Medicinal Chem20041210293610.1016/j.bmc.2003.12.003 16.MisraRNXiaoHWilliamsDKKimKSLuSKellerKAet al.Synthesis and biological activity"/>
 <result pre="of substituted 4-aryloxy- and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast" exact="cancer" post="cell proliferationBioorg Medicinal Chem20041210293610.1016/j.bmc.2003.12.003 16.MisraRNXiaoHWilliamsDKKimKSLuSKellerKAet al.Synthesis and biological activity"/>
 <result pre="al.Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced" exact="breast cancer." post="A phase 1b Clin trialJAMA Oncol20195e184475.10.1001/jamaoncol.2018.447530543347 19.ConroyAStockettDEWalkerDArkiMRHochUFoxJAet al.SNS-032 is"/>
 <result pre="novel therapeutic agentsPLoS ONE20149e10274110.1371/journal.pone.010274125048812 22.SahaSKGordanJDKleinstiverBPVuPNajemMSYeoJet al.Isocitrate dehydrogenase mutations confer dasatinib" exact="hypersensitivity" post="and SRC dependence in intrahepatic cholangiocarcinomaCancer Discov201667273910.1158/2159-8290.CD-15-144227231123 23.JohnsonFMAgrawalSBurrisHRosenLDhillonNHongDet al.Phase"/>
 <result pre="with advanced solid tumorsCancer201011615829110.1002/cncr.2492720108303 24.SharmaPCBansalKKSharmaASharmaDDeepAThiazole-containing compounds as therapeutic targets for" exact="cancer" post="therapyEur J Medicinal Chem202018811201610.1016/j.ejmech.2019.112016 25.Garcia-EgidoEWongSYFWarringtonBHHantzschAsynthesis of 2-aminothiazoles performed in"/>
 <result pre="acetamide as a novel scaffold active against sensitive and resistant" exact="cancer" post="cellsJ Medicinal Chem20165982769210.1021/acs.jmedchem.6b00547 41.El-SubbaghHIAbadiAHLehmannJSynthesis and antitumor activity of ethyl"/>
 <result pre="heterocycles containing sulfur atom: linear and angular thiazonaphthalimides against human" exact="lung cancer" post="cell in vitroBioorg Medicinal Chem20071568465110.1016/j.bmc.2007.07.008 68.LefrancFXuZBurthPMathieuVRevelantGFariaMVdCet al.4-Bromo-2-(piperidin-1-yl) thiazol-5-yl-phenyl methanone"/>
 <result pre="containing sulfur atom: linear and angular thiazonaphthalimides against human lung" exact="cancer" post="cell in vitroBioorg Medicinal Chem20071568465110.1016/j.bmc.2007.07.008 68.LefrancFXuZBurthPMathieuVRevelantGFariaMVdCet al.4-Bromo-2-(piperidin-1-yl) thiazol-5-yl-phenyl methanone"/>
 <result pre="thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K+-ATPase and Ras oncogene activity in" exact="cancer" post="cellsEur J Medicinal Chem2013632132310.1016/j.ejmech.2013.01.046 69.WalaaSMohamedNAWeamSNossierESMahmoudKSynthesis, molecular modeling studies and"/>
 <result pre="microwave assisted synthesis of 2-aminothiazoles and oxazoles and their anti" exact="cancer" post="activityIndo Am J Pharm Res2015555561 73.GorczynskiMJLealRMMooberrySLBushwellerJHBrownMLSynthesis and evaluation of"/>
 <result pre="and evaluation of substituted 4-aryloxy-and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human" exact="breast cancer" post="cell proliferationBioorg Medicinal Chem20041210293610.1016/j.bmc.2003.12.003 74.BorkovÃ¡LFrydrychIJakubcovÃ¡NAdÃ¡mekRLiÅ¡kovÃ¡BGurskÃ¡Set al.Synthesis and biological evaluation"/>
 <result pre="evaluation of substituted 4-aryloxy-and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of human breast" exact="cancer" post="cell proliferationBioorg Medicinal Chem20041210293610.1016/j.bmc.2003.12.003 74.BorkovÃ¡LFrydrychIJakubcovÃ¡NAdÃ¡mekRLiÅ¡kovÃ¡BGurskÃ¡Set al.Synthesis and biological evaluation"/>
 <result pre="al.Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic" exact="lymphoma" post="kinase (ALK) inhibitorsEur J Medicinal Chem2014864384810.1016/j.ejmech.2014.09.003 107.ChenXZhaoSWuYChenYLuTZhuYet al.Design, synthesis"/>
 <result pre="agentAsian J Res Biochem20183116 115.El-KarimSSASyamYMEl KerdawyAMAbdelghanyTMNew thiazol-hydrazono-coumarin hybrids targeting human" exact="cervical cancer" post="cells: synthesis, CDK2 inhibition, QSAR and molecular docking studiesBioorg"/>
 <result pre="J Res Biochem20183116 115.El-KarimSSASyamYMEl KerdawyAMAbdelghanyTMNew thiazol-hydrazono-coumarin hybrids targeting human cervical" exact="cancer" post="cells: synthesis, CDK2 inhibition, QSAR and molecular docking studiesBioorg"/>
</results>
